Cargando…
Are all prostate cancer patients "fit" for salvage radiotherapy?
The indication for salvage radiotherapy (RT) (SRT) in patients with biochemically-recurrent prostate cancer after surgery is based on prostate-specific antigen (PSA) levels at the time of biochemical recurrence. Although there are clear criteria (pT3-pT4 disease and/or positive margins) for the use...
Autores principales: | González-San Segundo, Carmen, Gómez-Iturriaga, Alfonso, Couñago, Felipe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935690/ https://www.ncbi.nlm.nih.gov/pubmed/31976305 http://dx.doi.org/10.5306/wjco.v11.i1.1 |
Ejemplares similares
-
Metastatic hormone-sensitive prostate cancer: How should it be treated?
por: López-Campos, Fernando, et al.
Publicado: (2021) -
Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease
por: Henriquez, Ivan, et al.
Publicado: (2021) -
Magnetic resonance imaging for prostate cancer before radical and salvage radiotherapy: What radiation oncologists need to know
por: Couñago, Felipe, et al.
Publicado: (2017) -
MRI detected extaprostatic extension (EPE) in prostate cancer: Do all T3a patients have the same outcomes?
por: Gomez-Iturriaga, A., et al.
Publicado: (2020) -
Salvage brachytherapy for locally recurrent prostate cancer after single-fraction 19 Gy high-dose-rate brachytherapy: toxicity, prostate-specific antigen kinetics, and cancer control
por: Mayrata, Esther, et al.
Publicado: (2021)